SCHEMBL2784228

SCHEMBL2784228

Cc1cc2ccccn2c1-c1ccc(NC(=O)Oc2snnc2C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.42
▸ RAB9A P51151 4/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ ALDH1A1 P00352 6/20 0.41
▸ L3MBTL1 Q9Y468 4/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ MAPT P10636 6/20 0.39
▸ POLB P06746 2/20 0.39
▸ LMNA P02545 3/20 0.37
▸ PORCN Q9H237 1/20 0.36
▸ HTT P42858 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ GAA P10253 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ TDP1 Q9NUW8 2/20 0.33
▸ RECQL P46063 1/20 0.33
▸ ALOX12 P18054 1/20 0.33
▸ GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1829193 0.83 LMNA (0.58) KDM4ERAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL16456582 0.72 MAPK14 (0.43) KDM4EALDH1A1MAPTPOLBLMNA
SCHEMBL2787427 0.71 STIM1 (0.48) KDM4ERAB9ASMN1; SMN2ALDH1A1MEN1
SCHEMBL16810760 0.70 MAPT (0.47) KDM4ERAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL16456523 0.70 PORCN (0.52) RAB9AMEN1KMT2APORCNNPC1
SCHEMBL2785129 0.69 MAPT (0.41) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL17644787 0.69 IL2 (0.59) RAB9ASMN1; SMN2MAPTLMNANPC1
SCHEMBL8297617 0.68 RAB9A (0.51) KDM4ERAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL16456528 0.68 ABL1 (0.42) PORCN
SCHEMBL16456595 0.68 MAPK14 (0.37) MEN1KMT2AMAPTPOLBPORCN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651232-B1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP (US) 2010-12-22 — — EP claimed
Send feedback